Triple combination treatment of trastuzumab, chemotherapy and immune checkpoint inhibitor in HER2 positive unresectable, locally advanced, metastatic gastric and esophageal adenocarcinoma: A ...
Fatty-acid-binding proteins as a novel target for the treatment of anti-PD-1-resistant tumors. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a ...
Cholangiocarcinoma (CCA) is considered as a diverse group of epithelial cancers characterized by poor outcomes. Cholangiocarcinoma can be divided into three types according to the original position: ...
Combining PD-L1 blockade with pharmacological HPK1 inhibition overcomes tumors with low antigenicity
An article by Daiichi Sankyo Co. Ltd. scientists reports data from a study designed to assess the potential of combining pharmacological inhibition of hematopoietic progenitor kinase 1 (HPK1) with ...
Cholangiocarcinoma (CCA) is considered as a diverse group of epithelial cancers characterized by poor outcomes. Cholangiocarcinoma can be divided into three types according to the original position: ...
- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in the tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback